Profile (CV) of the research teaching staff

Aguiló Anento, Juan Ignacio
Department: Departamento de Microbiología, Pediatría, Radiología y Salud Pública
Field: Inmunología
Faculty: Facultad de Medicina

Research Institute: INSTITUTO INVESTIGACIÓN SANITARIA DE ARAGÓN (IIS)
Group: B35_23R: Genética de micobacterias (GENMICO)

Number of 6-year periods of research productivity evaluation
  • CNEAI agreement periods of research evaluation. 25/06/24. (3)
Academic position: Prof. Ayudante Doctor
Office phone: 976755013
Email: naguilo@unizar.es
ORCID number: 0000-0001-7897-9173

Research interests
  • Ciencias naturales y ciencias de la salud

University degrees
  • Licenciado en Bioquímica. Facultad de Ciencias. 2002

PhDs
  • Doctor en Bioquímica. Facultad de Ciencias. 2009

Go to ORCID page

 
                 
Juan Ignacio Aguiló has been with the GENMICO Group since 2009, first as a post-doctoral researcher, and since 2016 as an independent researcher in his own lines of research. Since his incorporation, he has actively participated in the different steps to support the development of MTBVAC: from the preclinical characterization of the vaccine to clinical development. He planned and coordinated the preclinical experiments with mice required by the Swiss health authorities (Swissmedic) to obtain authorization to bring MTBVAC to the first clinical trial in humans, something that was achieved in 2012. In this way, MTBVAC was the first vaccine based on M tuberculosis that has been tested in humans. (Spertini et al, 2015, Lancet Resp Med). He also participated in the preparation of the clinical protocol for phase Ib, carried out in South Africa (Tameris et al, 2019, Lancet Resp Med), as well as phase IIa, which is currently underway in adults and neonates. Currently, he is also involved in the preparation of the phase III efficacy trial, which is expected to begin in 2022. The results derived from his manuscript published in Nature Communications in 2017 (as lead author) represent the basis for designing a trial. new trial under development to differentiate people vaccinated with MTBVAC from those infected with tuberculosis.
As an independent researcher, Juan Ignacio Aguiló has led his own lines of research since 2016, based on the search for new immunotherapeutic applications of live tuberculosis vaccines for diseases other than tuberculosis, including cancer and allergies. From 2016 to 2020, he has published 11 manuscripts as main or corresponding author (9 in first quartile journals, of which 5 in first decile). He has supervised three complete doctoral theses and another four in progress. In 2018 he obtained a position as Senior Researcher at the University of Zaragoza, which allowed him to request his own financing, obtaining two national projects COLLABORATION RETOS and INVESTIGATION RETOS in 2018 and 2019, respectively. In addition, he has contributed as inventor of three European patents since 2016 in the context of tuberculosis vaccines, all of them licensed to the company BIOFABRI.
Throughout these years he has received several awards for his research career. In 2009 he received the Extraordinary Doctorate Award from the University of Zaragoza. In 2016, he was awarded the Early Career Scientist Award by CTVD (Collaboration for TB Vaccine Discovery), a consortium for the search for tuberculosis vaccines based in Seattle (USA), Funded by the Bill Foundation and Melinda Gates. In 2019, he received the “Rafael Premio Gómez-Lus” award from the Real Academia de Medicina de Zaragoza, for the best national publication in Microbiology.

© University of Zaragoza | Versión 2.27.3
© Computing and Communications Service of the University of Zaragoza (Pedro Cerbuna 12, 50009 ZARAGOZA - SPAIN)